This trial will test the hypothesis that among 20 children and adolescents from Children's
Hospital, Boston with Crohn's disease, ulcerative colitis, systemic-onset juvenile rheumatoid
arthritis, juvenile dermatomyositis, systemic lupus erythematosus, mixed connective tissue
disease and vasculitis, treatment of glucocorticoid-associated osteopenia and osteoporosis
with 18 months of alendronate (FOSAMAX®, Merck & Co., Inc.) will result in greater
improvement in the mean change of individual AP spine bone mineral density (BMD) (gm/cm2)
determined by dual energy X-ray absorptiometry (DXA) than treatment with 18 months of
standard of care therapy.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital
Collaborators:
Elizabeth Glaser Pediatric AIDS Foundation Glaser Pediatric Research Network